
aug pm et
summari compani develop manufactur market proprietari specialti health care
product eye care women health
nm price-to-earnings oper ep
custom tend brand loyal come
contact lens howev off-set increas
competit contact lens new technolog
laser surgeri
past perform indic futur perform reli upon
analysi prepar equiti analyst
jun pm stock trade
star recommend
recent chang hold
buy highlight section stock
report updat accordingli
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra lower
maintain target
ep
estim multipl
higher end coo five-year rang
appropri given recent
higher growth margin profil july-q ep
vs lower
estim lower oct ep
ep
july-q sale increas
million coopervis revenu
million coopersurg csi
revenu coo lower ep quarter
due higher interest expens
lower oper margin invest
sell market think
thesi mostli play
limit near-term upsid invest
futur growth opportun result
downward revis ep estim henc
lower opinion share
hold /kevin huang cfa
dec ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview compani develop manufactur market health care product
two busi unit coopervis coopersurg csi account net
sale fy oct csi repres balanc
coopervis develop manufactur market broad rang contact lens world-wide vision
care market contact len market two major product categori spheric lens includ
lens correct near- farsighted uncompl complex visual defect toric
multifoc lens includ lens addit correct near- farsighted address
complex visual defect astigmat presbyopia sale fy product categori
broke follow single-us sphere non-singl use sphere toric len
multi-foc len sale fy geograph market america emea
coopersurg offer broad array product servic focus advanc health famili
portfolio product servic focus women health includ medic devic
fertil genom diagnost contracept csi offer product technolog servic
clinician patient world-wide csi collabor clinician identifi product new
technolog dispos product diagnost test sophist instrument equip
bring new product market csi also compet global invitro fertil ivf market
product portfolio ivf media assist reproduct technolog solut design enhanc
work fertil profession benefit famili
major develop januari acquir ocular scienc osi fifth largest contact
len manufactur billion cash stock acquisit osi made third
largest manufactur term market share provid access new technolog
particularli patent silicon hydrogel single-us len technolog new geograph market
particularli japan germani higher volum manufactur process juli acquir
origio maker in-vitro fertil product million august compani acquir
ltd european manufactur distributor soft contact lens
solut billion acquisit provid daili contact lens offer
clariti brand single-us sphere toric multi-foc silicon hydrogel lens august
acquir reprogenet llc genet laboratori special servic offer preimplant
genet screen preimplant genet diagnosi use ivf process million
may complet acquisit recombin inc base clinic genet test compani
special carrier screen million novemb wallac ivf segment
smith medic intern million novemb acquir paragard product line
billion paragard non-hormon copper intrauterin devic
approv birth control
market profil total world-wide sale soft contact lens increas calendar latest
avail approxim billion accord compani categori global sale sphere
market toric lens multifoc single-us lens
account total market modal repres geograph market
america account total sale emea asia/pacif
base compani data account almost global soft contact len market
johnson johnson vistakon divis alcon divis novarti ag
bausch lomb compani account remain told world-wide
contact len market like continu grow mid-singl digit annual next five year
advanc len technolog silicon hydrogel materi drive adopt contact
lens view howev compet technolog includ laser vision surgeri becom cheaper
preval len manufactur face addit competit threat
financi trend fy net sale increas billion billion fy
octob total cash short term invest balanc million
billion long-term debt
presid
senior vice-president financ
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc august technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
cut job act decemb see
develop neg health care
suppli compani fewer custom
like enrol insur plan start
would like lead higher
uncompens care rate hospit
facil turn would ultim lead
lower demand health care suppli
hospit facil largest
consum health care suppli
see demand health care suppli
continu driven replac cycl
time grow same-facil
patient admiss increasingli fuel
age longer-liv popul meanwhil
still see modest growth number
procedur perform off-set price
pressur reimburs risk
also remot possibl health care
suppli sub-industri could affect
tariff major trade
year date june health
increas composit index
 health suppli index
rose vs increas
neutral fundament outlook
health care suppli sub-industri next
month see continu robust growth
emerg market china potenti
slower growth demand could
pressur lower expect hospit
budget result action
care suppli basic hospit suppli
steril equip bed stretcher
histor recession-resist
health care reform law enact
 afford act
neutral effect health care suppli
sub-industri view benefit
greater number insur patient
off-set price pressur fee medic
devic tax sought rais total
billion year took effect
measur respons medic devic
excis tax suspend sinc
begin suspend till
end compani health care
suppli sub-industri stand benefit
medic devic tax repeal
develop question even
tax repeal mani compani
deriv increas portion revenu
non-u market subject
benefit health care suppli compani
million previous uninsur individu
came insur coverag
recent republican administr
 difficulti attempt
repeal stop medicaid expans
senat fail multipl time
gather suffici number vote pass
variou repeal replac bill howev
republican success elimin
individu mandat passag tax
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
compani inc keep target
fy oct ep estim roughli line peer reflect improv
sale growth outlook expect modest margin expans driven
product mix shift rais fy fy ep estim
report jul-q oper ep vs
consensu jul-q sale increas driven growth
coopervis increas toric categori expect sale
growth fy aid strength emea asia pacif region /k snyder
compani inc rais target
fy oct ep estim slight premium peer
reflect improv sale growth margin expans expect
increas fy fy ep estim
report apr-q oper ep vs
consensu apr-q sale increas growth vision aid
increas asia pacif region growth surgic expect
sale growth fy continu expand faster overal
per compani inc rais target
fy oct ep estim multipl slight
premium peer reflect sale growth outlook expect modest
margin expans product mix shift increas fy fy ep
estim jan-q oper ep
vs capit iq consensu sale increas
growth vision growth surgic acquisit driven
growth fertil see sale growth fy aid market share
analyst research note compani news
et cfra lower opinion share cooper compani
inc hold buy maintain target
ep estim multipl
higher end coo five-year rang
appropri given recent higher growth margin profil july-q ep
vs lower estim lower oct
ep ep july-q sale
increas million coopervis revenu
million coopersurg csi revenu coo lower ep
quarter due higher interest expens lower oper margin
invest sell market think thesi
mostli play limit near-term upsid invest
futur growth opportun result downward revis ep
estim henc lower opinion share hold /kevin
et cfra maintain buy opinion share cooper
compani inc maintain target
in-lin peer ep estim
multipl near averag coo five-year rang
april-q ep vs higher estim
rais oct ep april-q sale increas
million coopervis revenu million
coopersurg revenu million expect pro-forma
revenu growth strong diversifi growth asia
pacif region continu momentum daili silicon hydrogel lens
coopersurg segment revenu growth driven coo late
acquisit paragard see potenti make strateg
acquisit near futur opportun present
expect pay debt /kevin huang cfa
compani inc rais target
fy oct ep estim line peer reflect
sale growth margin expans expect increas fy fy
ep estim report jan-q
oper ep vs consensu forma sale
increas growth vision partial off-set declin
surgic impact declin genet test see pro forma
sale growth fy driven vision market share gain recoveri
inc keep target fy
oct ep estim roughli line peer continu see improv
sale growth modest margin expans rais fy ep estim
adjust acquisit paragard expect fy
ep report oct-q oper ep vs line
consensu fy pro forma sale increas driven growth
coopervis growth coopersurg expect organ sale growth
fy aid strong growth asia pacif region /danni yang cfa
inc announc sign agreement purchas
global right paragard intrauterin devic teva pharmaceut
billion paragard current sold revenu
approxim million trail twelve-month period deal
subject customari close condit expect close end
financ transact bridg loan eventu
long term debt view deal posit given
accret operating/gross margin ep within first year /k
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
